RareResearch.AI
← Back to atlas

N714S

Category 3/4 — Most DruggableLikely pathogenicLumenal · predictedσ-1 candidateEditorial
AsparagineSerine at position 714 · C-terminal lumenal domain (653-869) · WFS1 (Wolframin)

Asparagine → Serine at position 714 in wolframin's C-terminal lumenal domain. ClinVar Likely pathogenic for DFNA6 hearing loss. AlphaMissense 0.640 (just above threshold), DynaMut2 ΔΔG -0.49 kcal/mol (destabilising). Third Atlas variant at position 714 (with N714T, N714K).

Interactive 3D Structure

Wild-type reference
Wild-type N714 — hydrogen bond to I767
Fullscreen ↗
DynaMut2 mutant · N714S
Mutant S714 — hydrogen bond to A716 lost (7 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

7 lost1 gained6 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondA716Lost
Hydrogen bondE717E717Preserved
Hydrogen bondS718S718Preserved
Hydrogen bondI767Lost
Hydrogen bondD771D771Preserved
Polar contactA716Lost
Polar contactE717E717Preserved
Polar contactS718S718Preserved
Polar contactI767Lost
Polar contactD771Lost
Van der WaalsA716Lost
Van der WaalsE717E717Preserved
Van der WaalsS718Gained
HydrophobicE717Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.49kcal/mol
Destabilising — mild
AlphaMissense
0.640
LPath
AlphaFold pLDDT
87
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationLikely pathogenic
Review statuscriteria provided, single submitter
Associated conditionsAutosomal dominant nonsyndromic hearing loss 6 (DFNA6)
InheritanceDFNA6 hearing loss documented.
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.2141A>G
ClinVar accessionVCV003387796
Last evaluated2024/11/08 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Structural Context

Position 714 same neighbor environment as N714T and N714K: SER715 (2.4 Å), ASP713 (2.5 Å), PHE770 (4.4 Å), ALA716 (4.4 Å), ASP771 (4.7 Å — partner of D771H Atlas card).

N714S is the most conservative substitution in the N714 series — replacing asparagine with serine preserves H-bonding capacity but changes the geometry from amide to hydroxyl. The D713-N714-D771 polar network reorganizes; the new S714 hydroxyl is shorter than asparagine's amide arm.

The |ΔΔG| of 0.49 reflects fold accommodation. AlphaMissense's 0.640 is the lowest in the N714 series — borderline above the 0.564 threshold — yet ClinVar Likely Pathogenic with DFNA6 establishes clinical pathogenicity. The mechanism is fine-grained H-bond network adjustment.

Amino-acid chemistry
Asparagine (N) → Serine (S) — polar amide replaced by polar hydroxyl. Both H-bond capable but different geometry.
Position in the protein
C-terminal lumenal domain · position 714 in the ER lumen (pLDDT 87). Same position as N714T and N714K.

Druggability Assessment

Category 3/4 — Most Druggable. |ΔΔG| = 0.49 — fold survives. AlphaMissense 0.640 borderline + DFNA6 confirm pathogenic consequence.

Mechanism is fine-grained H-bond network reorganization at the D713-N714-D771 polar cluster. Therapeutic strategy: same microregion as N714T, N714K, D771H.

Why this matters

N714S is the THIRD pathogenic substitution at position 714 (with N714T, N714K). Position 714 + the D713-D771-K768 polar network is one of the most multi-variant target hubs in the Atlas.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the N714S PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download N714S PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Topological domain653869 · Lumenal